Health Canada issued a Q&A document on the request to evaluate the risk of the presence of N-nitrosamine impurities in Human Pharmaceutical, Biological and Radiopharmaceutical products
HC QnA Document on Nitrosamines - Update 2 (ver. 2020-12-15) (final).pdf (550.5 KB)
MAH Letter_ENGLISH (Final)_BRDDsign.pdf (220.9 KB)